Estil Vance is an Oncology physician. OpenAlex indexes 49 publications with 1,314 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7777 Forest Ln Ste D220
Dallas, TX 752302571
Telephone
972-566-7790Provider last certified this registry record 24 Aug 2022.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- ABBVIE INC.Program year20251 payment
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
38%Corticosteroid38%Dexamethasone sodium phosphate100%Part B, office-administered≥16 patientsDermatology
15.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.2%Acyclovir100%Part D≥23 patientsCorticosteroid3.5%Triamcinolone Acetonide100%Part D≥13 patientsCancer & immunology
10.1%Thalidomide Analog3.9%Revlimid100%Part D<11 patientsCalcineurin inhibitor2.9%Tacrolimus100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
Biology of Blood and Marrow Transplantation
2025 - 183 Primary Care Curriculum for Emergency Medicine Residents Enhances Knowledge, Changes Practice
Annals of Emergency Medicine
2025 - Outpatient Administration of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma (NHL), in a Large Multi-Center Network
Biology of Blood and Marrow Transplantation
2024 - Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy
Biology of Blood and Marrow Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”